Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
OncoGenex reports updated survival data on OGX-011 in a second-line chemotherapy trial for patients with prostate cancer
May 27th, 2008
OncoGenex Technologies Inc. announced that updated Phase 2 data on the Company's lead cancer drug candidate, OGX-011, also referred to as custirsen, revealed encouraging outcomes in the treatment of patients with hormone refractory prostate cancer. Overall, custirsen was well-tolerated in combination with either docetaxel or mitoxantrone administered as second-line chemotherapy in patients with hormone refractory prostate cancer and was associated with durable pain responses in 50 percent or more of patients, a minimum of a 50 percent PSA decline in 27 percent or more of patients, and better than expected survival with 60 percent of patients alive at a median follow-up of 13.3 months. Top...
Source: Cancer Weekly (2008-05-27)
|
